Reports
Reports
Sale
The India vaccines market size is expected to grow at a CAGR of 13% during the forecast period of 2024-2032, driven by rising investment into the healthcare research and development along with increased government and private institution collaborations to develop effective vaccines across the region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
A vaccine is a biological preparation designed to provide acquired immunity against a disease. A vaccine may include the strain, toxin or one of the surface proteins of a dead or weakened microorganism that resembles the structure of a pathogen. Vaccines can be both therapeutic which offer immunity against a disease which has occurred or prophylactic which is administered to prevent the effects of an infection that may occur in the future.
The India vaccine market demand has seen a significant upswing especially after the sudden outbreak of COVID-19. With government’s continuous efforts and awareness programs to normalize the usage of vaccine, the masses have become more comfortable and familiar with vaccinations, which is expected to add to the market value in the forecast period as well.
Integrating latest technologies into vaccine development, India has successfully developed four indigenous COVID-19 vaccines namely ZyCoV-D- world’s first DNA Vaccine, India’s first protein subunit vaccine- CORBEVAXTM along with iNCOVACC, the first intranasal COVID-19 vaccine. In June 2023, GEMCOVAC™-19, world’s first mRNA vaccine was revealed as a part of the Mission COVID Suraksha program. Such initiatives indicate that the India vaccines market growth is certain in upcoming years.
Shifting focus from COVID-19, the region has been making strides in other areas of development as well. Under the partnership of Serum Institute of India and Panacea Biotec, the country is headed to develop its first dengue vaccine. The two companies have applied for an Expression of Interest for collaborative Phase III clinical trials, moving closer on getting the vaccination ready to hit the markets.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Disease Type
Market Breakup by Technology
Market Breakup by Product Type
Market Breakup by End User
Market Breakup by Distribution Channel
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The India vaccine market value is driven with advancements in technology, the rising manufacturing capability of vaccines and cold chain storage facilities. The introduction of the Universal Immunization Program (UIP) aimed at raising immunization coverage against treatable diseases in the nation has substantially increased the market growth. Within the span of 5 years, the region has vaccinated approximately 348 million children under the measles-rubella vaccination campaign occurring nationwide. With such potential, the region is set to add to the global vaccine market share as well.
The rising number of private companies in India has also aided the overall India vaccine market share. Many companies have made efforts to offer low-cost solutions and are gradually turning their attention to innovation to elevate their revenues. The government is also fostering expansion with the help of easing out the rules and regulations and inviting foreign investments to build a better medical research and development infrastructure. In view of these factors, India can emerge as a global manufacturing hub for vaccines in the forecast period.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Disease Type |
|
Breakup by Technology |
|
Breakup by Product Type |
|
Breakup by End User |
|
Breakup by Distribution Channel |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 India Vaccine Market Overview
3.1 India Vaccine Market Historical Value (2016-2022)
3.2 India Vaccine Market Forecast Value (2023-2031)
4 India Vaccine Market Landscape
4.1 India Vaccine Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 India Vaccine Product Landscape
4.2.1 Analysis by Disease Type
4.2.2 Analysis by Product Type
5 India Vaccine Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 India Vaccine Market Segmentation
6.1 India Vaccine Market by Disease Type
6.1.1 Market Overview
6.1.2 Pneumococcal
6.1.3 Influenza
6.1.4 DTP
6.1.5 HPV
6.1.6 MMR
6.1.7 COVID-19
6.2 India Vaccine Market by Technology
6.2.1 Market Overview
6.2.2 Recombinant
6.2.3 Toxoid
6.2.4 Conjugate
6.2.5 RNA
6.3 India Vaccine Market by Product Type
6.3.1 Market Overview
6.3.2 Monovalent
6.4 India Vaccine Market by End User
6.4.1 Market Overview
6.4.2 Adult
6.4.3 Children
6.5 India Vaccine Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospital and Clinical Pharmacies
6.5.3 Retail Pharmacies
6.5.4 Online Pharmacies
7 Funding Analysis
7.1 Analysis by Funding Instances
7.2 Analysis by Type of Funding
7.3 Analysis by Funding Amount
7.4 Analysis by Leading Players
7.5 Analysis by Leading Investors
7.6 Analysis by Geography
8 Partnership and Collaborations Analysis
8.1 Analysis by Partnership Instances
8.2 Analysis by Type of Partnership
8.3 Analysis by Leading Players
8.4 Analysis by Geography
9 Supplier Landscape
9.1 Bharat Biotech International Ltd
9.1.1 Financial Analysis
9.1.2 Product Portfolio
9.1.3 Demographic Reach and Achievements
9.1.4 Mergers and Acquisitions
9.1.5 Certifications
9.2 Serum Institute of India
9.2.1 Financial Analysis
9.2.2 Product Portfolio
9.2.3 Demographic Reach and Achievements
9.2.4 Mergers and Acquisitions
9.2.5 Certifications
9.3 Panecea
9.3.1 Financial Analysis
9.3.2 Product Portfolio
9.3.3 Demographic Reach and Achievements
9.3.4 Mergers and Acquisitions
9.3.5 Certifications
9.4 Cadila Pharmaceuticals Ltd
9.4.1 Financial Analysis
9.4.2 Financial Portfolio
9.4.3 Demographic Reach and Achievements
9.4.4 Mergers and Acquisitions
9.4.5 Certifications
9.5 Ranbaxy Lab
9.5.1 Financial Analysis
9.5.2 Product Portfolio
9.5.3 Demographic Reach and Achievements
9.5.4 Mergers and Acquisitions
9.5.5 Certifications
9.6 GSK Asia Pvt. Ltd
9.6.1 Financial Analysis
9.6.2 Product Portfolio
9.6.3 Demographic Reach and Achievements
9.6.4 Mergers and Acquisitions
9.6.5 Certifications
9.7 Sanofi Pasteur India Pvt Ltd
9.7.1 Financial Analysis
9.7.2 Product Portfolio
9.7.3 Demographic Reach and Achievements
9.7.4 Mergers and Acquisitions
9.7.5 Certifications
9.8 Human Biological Institute
9.8.1 Financial Analysis
9.8.2 Product Portfolio
9.8.3 Demographic Reach and Achievements
9.8.4 Mergers and Acquisitions
9.8.5 Certifications
9.9 Green signal BioPharma Ltd
9.9.1 Financial Analysis
9.9.2 Product Portfolio
9.9.3 Demographic Reach and Achievements
9.9.4 Mergers and Acquisitions
9.9.5 Certifications
9.10 Shantha Biotechnics Ltd
9.10.1 Financial Analysis
9.10.2 Product Portfolio
9.10.3 Demographic Reach and Achievements
9.10.4 Mergers and Acquisitions
9.10.5 Certifications
9.11 BIBCOL
9.11.1 Financial Analysis
9.11.2 Product Portfolio
9.11.3 Demographic Reach and Achievements
9.11.4 Mergers and Acquisitions
9.11.5 Certifications
9.12 Haffkine
9.12.1 Financial Analysis
9.12.2 Product Portfolio
9.12.3 Demographic Reach and Achievements
9.12.4 Mergers and Acquisitions
9.12.5 Certifications
9.13 HLL Biotech Ltd
9.13.1 Financial Analysis
9.13.2 Product Portfolio
9.13.3 Demographic Reach and Achievements
9.13.4 Mergers and Acquisitions
9.13.5 Certifications
9.14 BCG Vaccine
9.14.1 Financial Analysis
9.14.2 Product Portfolio
9.14.3 Demographic Reach and Achievements
9.14.4 Mergers and Acquisitions
9.14.5 Certifications
9.15 India Immunologicals Ltd.
9.15.1 Financial Analysis
9.15.2 Product Portfolio
9.15.3 Demographic Reach and Achievements
9.15.4 Mergers and Acquisitions
9.15.5 Certifications
10 India Vaccine Market - Distribution Model (Additional Insight)
10.1 Overview
10.2 Potential Distributors
10.3 Key Parameters for Distribution Partner Assessment
11 Key Opinion Leaders (KOL) Insights (Additional Insight)
12 Company Competitiveness Analysis (Additional Insight)
12.1 Very Small Companies
12.2 Small Companies
12.3 Mid-Sized Companies
12.4 Large Companies
12.5 Very Large Companies
13 Payment Methods (Additional Insight)
13.1 Government Funded
13.2 Private Insurance
13.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market is anticipated to grow at a CAGR of 13% during the forecast period of 2024-2032, driven by increasing investment into the healthcare research and development along with the emphasis on developing vaccines for chronic diseases.
The market demand has increased with the COVID-19 outbreak, which has made the masses more open and comfortable to utilizing vaccinations.
The current market trend revolves rising privatisation and collaborations amongst key companies. For instance, Serum Institute of India and Panacea Biotec are working on developing the nation’s first dengue vaccine.
The different technologies in the market include conjugate vaccines, recombinant vaccines, toxoid vaccines, and viral vector vaccines, among others.
The product types in the market include monovalent vaccines.
The indications can be categorised into pneumococcal, influenza, DTP, HPV, MMR and COVID-19.
Major end users include children and adults.
Major distribution channels include hospital and clinical pharmacies, retail pharmacies, and online pharmacies.
Key players involved in the market are Bharat Biotech International Ltd, Serum Institute of India, Panecea, Cadila Pharmaceuticals Ltd, Ranbaxy Lab, GSK Asia Pvt. Ltd, Sanofi Pasteur India Pvt Ltd, Human Biological Institute, Green signal BioPharma Ltd., Shantha Biotechnics Ltd, BIBCOL, Haffkine, HLL Biotech Ltd, BCG Vaccine and Indian Immunologicals Ltd.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.